

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} {[ size_append(item.pr_size_append, item.pr_am, item.pr_size) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | DOCK2 is an atypical Rac activator predominantly expressed in hematopoietic cells. CPYPP is a small-molecule inhibitor of DOCK2. It dose-dependently inhibited the nucleotide exchange factor activity of DOCK2DHR-2 for Rac1 with an IC50 value of 22.8±2.4μM. DOCK2 overexpression-induced activation of Rac in HEK293T cells was significantly suppressed by one-hour pretreatment with CPYPP (100μM). Pretreatment of T cells or B cells with CPYPP at a concentration of 100μM for one hour almost completely inhibited Rac activation in response to CCL21 or CXCL13, respectively. One-hour treatment with CPYPP at 100μM inhibited TCR-mediated Rac activation in T cells. Treatment with 100μM CPYPP severely impaired CpG-A-induced Rac activation in pDCs. Intraperitoneal administration of mice with 5mg of CPYPP one hour before adoptive transfer reduced the percentage of migrated T cells to < 25% as compared to the control group[1]. |
| 作用机制 | CPYPP is a small-molecule inhibitor of DOCK2 that reversibly binds to the DOCK2 DHR-2 domain and inhibited catalytic activity of DOCK2 in vitro[1]. |
| Concentration | Treated Time | Description | References | |
| SAS-DTX | 10 µM | 24 h | Induced cytoplasmic vacuolization and suppressed cell viability | Cell Biosci. 2024 Jun 10;14(1):78 |
| OECM1-DTX | 10 µM | 24 h | Induced cytoplasmic vacuolization and suppressed cell viability | Cell Biosci. 2024 Jun 10;14(1):78 |
| NCI-H1299 | 10 µM | 24 h | Induced cytoplasmic vacuolization and cell death | Cell Biosci. 2024 Jun 10;14(1):78 |
| PANC-1 | 10 µM | 24 h | Induced cytoplasmic vacuolization and cell death | Cell Biosci. 2024 Jun 10;14(1):78 |
| U-87 MG | 10 µM | 24 h | Induced cytoplasmic vacuolization and cell death | Cell Biosci. 2024 Jun 10;14(1):78 |
| DBTRG-05MG | 10 µM | 24 h | Induced cytoplasmic vacuolization and cell death | Cell Biosci. 2024 Jun 10;14(1):78 |
| MDA-MB-435 | 10 µM | 24 h | Induced cytoplasmic vacuolization and cell death, inhibited cell proliferation and clonogenic activity | Cell Biosci. 2024 Jun 10;14(1):78 |
| MDA-MB-231 | 10 µM | 24 h | Induced cytoplasmic vacuolization and cell death, inhibited cell proliferation and clonogenic activity | Cell Biosci. 2024 Jun 10;14(1):78 |
| human peripheral blood neutrophils | 100 μM | 60 min | inhibited fMLF-induced Rac2 activation, chemotaxis, and ROS production | J Immunol. 2014 Dec 1;193(11):5660-7 |
| RCC7T/E | 1–100μM | 24 h | Measure cell viability, EC50 was 16μM | Prostate. 2020 Sep;80(13):1045-1057 |
| VCaP | 1–100μM | 24 h | Measure cell viability, EC50 was 31–35μM | Prostate. 2020 Sep;80(13):1045-1057 |
| MDA-PCa2b | 1–100μM | 24 h | Measure cell viability, EC50 was 31–35μM | Prostate. 2020 Sep;80(13):1045-1057 |
| CD3+ T cells | 100 μM | 2 h | To evaluate the effect of CPYPP on chemotaxis of CD3+ T cells under CXCL12 stimulation. Results showed that CPYPP significantly inhibited CXCL12-induced chemotaxis (FC=0.57, P=1.0×10−7). | Nature. 2022 Sep;609(7928):754-760 |
| pDCs | 100 μM | 12 h | To evaluate the effect of CPYPP on IFNα production by pDCs under CpG stimulation. Results showed that CPYPP significantly reduced IFNα production (FC=5.5×10−5, P=0.0038). | Nature. 2022 Sep;609(7928):754-760 |
| Administration | Dosage | Frequency | Description | References | ||
| SCID mice | Breast cancer orthotopic xenograft model | Intraperitoneal injection | 30 mg/kg | Daily for 14 days | Significantly suppressed tumor growth and induced tumor cell vacuolization | Cell Biosci. 2024 Jun 10;14(1):78 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
3.08mL 0.62mL 0.31mL |
15.40mL 3.08mL 1.54mL |
30.79mL 6.16mL 3.08mL |
|
| CAS号 | 310460-39-0 |
| 分子式 | C18H13ClN2O2 |
| 分子量 | 324.76 |
| SMILES Code | O=C(C1=CC=CC2=CC=CC=C2Cl)NN(C3=CC=CC=C3)C1=O |
| MDL No. | MFCD00980987 |
| 别名 | |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 25 mg/mL(76.98 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1